📍Life expectancy ⤵️ by 3-4y for each decade diagnosis of #type2diabetes before 70y 📍driven by ⤴️ CV ☠️ 👉 important to manage all, but the #T2Day cohort especially need our attention @ShivaniM_KC @kamleshkhunti @Dralbalawi1989 https://t.co/WjonzXKeBl

#GLP1's & erectile function: friend or foe? 🔬 New Biomolecules review: mostly friend❗️ ✅ Improve endothelial function ✅ Boost testosterone via weight loss ✅ REWIND: dulaglutide cut ED risk (HR 0.92) Responses vary - ask at follow-up. 🔗 https://t.co/JHuRu3OrYE

💪🏾Mind the Muscle: Incretin Therapies for Weight Loss💪🏾 🔥The hottest of topics with incretin therapies🔥 Here's my last @Medscape perspective piece from @ObesitySociety @ObesityWeek congress in Atlanta - link in comments 👇🏾

Some personal reflections on the recent @gmcuk workforce report- along with @bmj_latest investigation regards the 'gig economy' being run by #NHS Trusts. The system has no idea what to do next- apart from warm words and a lot of hand wringing- especially with the situation

Insight delivered. Expertise shared. The first sessions of #CVRMUK2025 tackled emerging evidence in cardio-renal medicine. Key takeaways already echo across disciplines: integration matters. Looking forward to exploring how these insights translate to everyday clinical decisions.

Welcome to @CVRMUK London Autumn 2025!

#GLP1 is forcing Big Food to finally reform. Not through regulation, but ⤵️💰 12% of US adults on GLP-1s = ⤵️8.6% in household food spending. 🔹Ultra-processed foods hit hardest 🔸 $12bn potential loss for junk food. Nestlé, General Mills, even Greggs scrambling to

A pleasure as ever to speak to GP colleagues and primary care Thank you @pcdosociety for the invite Acknowledgement on behalf of @NHSEngland of the amazing work all do- and the key to improving #Diabetes outcomes Twas fun 🥰 @kamleshkhunti @scelee1

🚨 NEW GUIDANCE for CGM use and class 2 drivers 🚗 ➡️CGM now safe to use if class 2 drivers ONLY IF approved for non adjunctive use!! ✅ Do use our CGM comparison chart to check which ones will be safe to use here: 🔗 https://t.co/7xrp7qMQL4

The Yale Obesity Symposium A one-day 7 CME event November 21 2025 NEW developments in Obesity Treatment Speakers including: Lee Kaplan MD PhD Ania Jastreboff MD PhD John Morton MD Register NOW! https://t.co/XHUngidT2V @Yale @YaleMed @YaleSurgery Obesity GLP-1ra

❗️A trial we have kept an eye on announces primary outcome met ❗️ FINE-ONE Finerenone in T1DM potentially provides an opportunity to address renal risk (maybe more) in this population with unmet need https://t.co/1Hb6fsg5Dh @AmarPut @drpatrickholmes @kamleshkhunti

As promised? Communication out to all outstanding 9/42 ICS re implementation of NG 28 @NICEComms (published March 2022) via @NHSEngland One of the last few things to hopefully close down before end March 2026 @kamleshkhunti @scelee1 @docwas @DiabetesUK

💊 SGLT2 inhibitors & phimosis risk in men with T2D 📍 Danish cohort study (2016–2021) comparing SGLT2i vs GLP-1RA initiators 📊 1-year phimosis risk: 0.9% vs 0.5% → RR 1.88 (95% CI 1.43–2.47) 📊 8-year risk: 4.8% vs 3.6% → RR 1.36 (95% CI 1.14–1.61) ⚠️ Risk remains

Some basics to remember!!! And it may help save a life Check for #T1Diabetes at the slightest suspicion Please cascade to colleagues and keep at improving awareness Thank you (Poster via @DiabetesUK) #gbdoc 💙

Next week- we have @diabetespc in Olympia, London Looking forward to talking about progress made in #T1Diabetes; Access to #Technology; #T2D update re CGM - and of course-what comes next If there- come and say hello! And ask what you want 🙂 (Nearly) a decade in @NHSEngland

💡The first step in healthcare is self-care 🔥My latest @Medscape Medical Mentor podcast is live! 🚨Improving cardiometabolic health in #T2D, focusing on the importance of 24-hour physical behaviours for people living with #T2D or the 5 𝗦's On @Spotify & @ApplePodcasts

10% of individuals use GLP-1ra Glucagon-Like Peptide-1 Agonists after Undergoing Bariatric Surgery in the US #Diabetes #obesity #bariatricsurgery @JAMA Surgery @JAMA Network

📊 Meta-analysis of 10 GLP-1RA RCTs · ↓ MACE by 14% · ↓ HF hospitalisation + kidney outcomes 👉 Glycaemic control, not weight loss, associated with CV benefits of GLP-1RAs https://t.co/lEINyKUKUJ

Really proud of @nicmiln launching her book Oxford Handbook of Diabetes Nursing A must read!

#LylasLaw 💛💝🌻 https://t.co/Z8oBv9DPDk

@SABOURETCardio @pabeda1 @ADA_DiabetesPro ❗️and the results❗️ 🔹non-inferiority of Tirzepatide to Dulaglutide 🔸Superiority thresholds NOT met 🔹Great all cause mortality separation